{"id":445,"date":"2015-03-18T16:51:26","date_gmt":"2015-03-18T20:51:26","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=445"},"modified":"2015-03-18T16:51:26","modified_gmt":"2015-03-18T20:51:26","slug":"secondaries-announced-3-18-2015","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/secondaries-announced-3-18-2015\/","title":{"rendered":"Secondaries announced 3.18.2015"},"content":{"rendered":"

IPOBoutique.Com rates secondary offerings to hit the tape with a \u2018BUY\u2019, \u2018NEUTRAL\u2019 or \u2018AVOID\u2019 rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary\u2019s he\u2019s issued with a \u2018BUY\u2019 rating.<\/p>\n

Company: Esperion Therapeutics
\nSymbol: ESPR
\nPrice: Last trade $99.60
\nTrade Date: 3\/19
\nShares: 1.5 million
\nUnderwriter(s) Credit Suisse, RBC Capital Markets, UBS Securities
\nRating=Subscription Needed<\/a><\/p>\n

Company: Cellectis, Inc.
\nSymbol: CLLS
\nPrice: Last trade $36.83
\nDescription: Their ordinary shares are listed on the Alternext market of Euronext in Paris under the symbol ‘ALCLS’.
\nTrade Date: 3\/26
\nShares: 3.5 million ADSs
\nUnderwriter(s) BofA Merrill Lynch, Jefferies, Piper Jaffray
\nCo Manager(s) Oppenheimer & Co., Trout Capital
\nRating=Subscription Needed<\/a><\/p>\n

Company: Assembly Biosciences
\nSymbol: ASMB
\nPrice: Last trade $13.87
\nTrade Date: 3\/19
\nShares: 5.4 million
\nUnderwriter(s) Credit Suisse, William Blair
\nRating=Subscription Needed<\/a><\/p>\n

Company: Garrison Capital Inc.
\nSymbol: GARS
\nPrice: Last trade $15.00
\nTrade Date: 3\/19
\nShares: 809,000
\nUnderwriter(s) Robert Baird & Co.
\nRating=Subscription Needed<\/a><\/p>\n

Company: Concert Pharmaceuticals
\nSymbol: CNCE
\nPrice: Last trade $16.55
\nTrade Date: 3\/19
\nShares: 3.02 million
\nUnderwriter(s) Wells Fargo Securities, JMP Securities
\nRating=Subscription Needed<\/a><\/p>\n

Company: Horizon Technology
\nSymbol: HRZN
\nPrice: Last trade $14.30
\nTrade Date: 3\/19
\nShares: 2.38 million
\nUnderwriter(s) Keefe, Bruyette & Woods, Oppenheimer & Co.
\nRating=Subscription Needed<\/a><\/p>\n

Company: Equity One
\nSymbol: EQY
\nPrice: Last trade $27.35
\nTrade Date: 3\/19
\nShares: 3.9 million
\nUnderwriter(s) Citigroup
\nRating=Subscription Needed<\/a><\/p>\n

Company: Tekmira Pharmaceuticals Corp.
\nSymbol: TKMR
\nPrice: Last trade $19.76
\nTrade Date: 3\/20
\nShares: 6 million
\nUnderwriter(s) Leerink Partners, RBC Capital Markets
\nRating=Subscription Needed<\/a><\/p>\n

Company: PDC Energy
\nSymbol: PDCE
\nPrice: Last trade $53.34
\nTrade Date: 3\/19
\nShares: 3.48 million
\nUnderwriter(s) Goldman Sachs, J.P. Morgan
\nRating=Subscription Needed<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IPOBoutique.Com rates secondary offerings to hit the tape with a \u2018BUY\u2019, \u2018NEUTRAL\u2019 or \u2018AVOID\u2019 rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary\u2019s he\u2019s issued with a \u2018BUY\u2019 rating. Company: Esperion Therapeutics Symbol: ESPR Price: Last trade $99.60 Trade Date: 3\/19 Shares: 1.5 million Underwriter(s) Credit Suisse, RBC Capital Markets, UBS[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[35],"tags":[236,235,238,240,234,237,239,242,241],"class_list":["post-445","post","type-post","status-publish","format-standard","hentry","category-secondary-offerings","tag-asmb","tag-clls","tag-cnce","tag-eqy","tag-espr","tag-gars","tag-hrzn","tag-pdce","tag-tkmr"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=445"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/445\/revisions"}],"predecessor-version":[{"id":446,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/445\/revisions\/446"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}